Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2014 May;19(5):670-9. doi: 10.1016/j.drudis.2013.11.021. Epub 2013 Dec 4.

GPR120 agonism as a countermeasure against metabolic diseases.

Author information

1
Centre for Chronic Disease Prevention and Management, College of Health and Biomedicine, Victoria University, Melbourne 8001, Australia.
2
Department of Physiology, The University of Melbourne, Melbourne 3010, Australia.
3
Centre for Chronic Disease Prevention and Management, College of Health and Biomedicine, Victoria University, Melbourne 8001, Australia. Electronic address: andrew.mcainch@vu.edu.au.

Abstract

Obesity, type 2 diabetes mellitus and cardiovascular disease are at epidemic proportions in developed nations globally, representing major causes of ill-health and premature death. The search for drug targets to counter the growing prevalence of metabolic diseases has uncovered G-protein-coupled receptor 120 (GPR120). GPR120 agonism has been shown to improve inflammation and metabolic health on a systemic level via regulation of adiposity, gastrointestinal peptide secretion, taste preference and glucose homeostasis. Therefore, GPR120 agonists present as a novel therapeutic option that could be exploited for the treatment of impaired metabolic health. This review summarizes the current knowledge of GPR120 functionality and the potential applications of GPR120-specific agonists for the treatment of disease states such as obesity, type 2 diabetes mellitus and cardiovascular disease.

PMID:
24315954
DOI:
10.1016/j.drudis.2013.11.021
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center